- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01826188
Combined THC and CBD Drops for Treatment of Crohn's Disease
Combined THC and CBD Drops for Treatment of Crohn's Disease, a Phase II Double Blind Placebo Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The investigators have recently published a retrospective observational study about the beneficial effect of cannabis in Crohn's disease. The investigators have also concluded a double blind placebo controlled study of Inhaled cannabis in the treatment of Crohn's disease. Both studies have shown significant symptomatic improvement of disease. However, objective parameters of inflammation were not measured. The question arises as to whether the observed improvement is merely symptomatic or due to a real change in inflammation. In addition, administration per os is a healthier option than smoking but the efficacy of oral cannabis was not investigated.
The aim of the proposed study in to evaluate the efficacy of drops of cannabis oil in crohn's disease patients compared to placebo. Treatment success will be defined as a decrease of at least 100 points in CDAI after 8 weeks of treatment.
Secondary aims:
- Remission of disease i.e CDAI of less the 150 points.
- Improvement of at least one point in Endoscopic disease activity index
- Improvement of CRP and calprotectine
- Improvement of blood cytokine levels
- Improvement of at least 30 points in quality of life as measured by the SF 36. In addition the investigators will monitor side effects by questionnaires addressed to the patients and to a significant relative of the patients.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Kfar Saba, Israel
- Meir Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with a diagnosis of Crohn's disease of at least 3 months duration, which was proved by either endoscopy or appropriate imaging study.
- Patients who have failed treatment with either 5 ASA or corticosteroids or immunomodulators or biologic agents, or steroid dependant patients, or patients who were treated by the above mentioned drugs and could not tolerate them due to side effects.
- Age 20 or older.
- Able to sign informed concent
Active Crohn's disease with a CDAI 200 or more.
-
Exclusion Criteria:
- Patients with a diagnosis of a mental disorder
- Patients who by the judgment of their physician are likely to develop drug addiction.
- Pregnant women or women who are intending to become pregnant
- Patients with a known cannabis allergy
- Patients who are not capable of giving an informed consent
Patients with an impending operation due to Crohn's disease.
-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: THC 5 mg/ml and CBD 50 mg/ml.
olive oil containing THC 5 mg/ml and CBD 50 mg/ml.
which will be taken twice daily.
|
olive oil containing THC and CBD
|
Placebo Comparator: Placebo
olive oil but without any active ingredients.
|
olive oil without cannabis
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment sucsess will be defind as a decrease of at least 100 points in CDAI after 8 weeks of treatment.
Time Frame: 8 weeks
|
The aim of the proposed study in to evaluate the efficacy of drops of cannabis oil in crohn's diseas patients compared to placebo.
Treatment sucsess will be defind as a decrease of at least 100 points in CDAI after 8 weeks of treatment.
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Remission of disease
Time Frame: 8 weeks
|
1. Remission of disease i.e CDAI of less the 150 points.
|
8 weeks
|
endoscopic improvment
Time Frame: 8 week
|
2. Improvment of at least one point in Endoscopic disease activity index
|
8 week
|
Improvment of CRP and calprotectine
Time Frame: 8 week
|
CRP and calprotectine will be measured before and after 8 weeks of study treatment
|
8 week
|
Improvment of blood cytokine levls
Time Frame: 8 weeks
|
blood cytokine levls including IL-10, TNF, and IL 23 will be measured before and at the end of the study
|
8 weeks
|
Improvment of at least 30 points in quality of life as measured by the SF 36.
Time Frame: 8 weeks
|
patients will answer a short form of Health related quality of life quasionnair before and at the end of the study.
|
8 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and side effects
Time Frame: 8 weeks
|
we will monitor side effects by questionnairs adressed to the patients and to a significant relative of the patients.both
patient and a significant realitive (parent, spouse) living in the same residence with the patient will recive a quationnair monitiring cannabis use, with aminimus score of 0 (not dependant, no side effects) to a maximum score of 15 (very dependant, sever side effects)
|
8 weeks
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0196-12-MMC
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Crohn's Disease
-
ProgenaBiomeRecruitingCrohn Disease | Crohn Colitis | Crohn's Ileocolitis | Crohn's Gastritis | Crohn's Jejunitis | Crohn's Duodenitis | Crohn's Esophagitis | Crohn's | Crohn Disease of Ileum | Crohn Ileitis | Crohn's Disease Relapse | Crohns Disease Aggravated | Crohn Disease in Remission | Crohn's Disease of PylorusUnited States
-
Massachusetts General HospitalAmerican College of GastroenterologyNot yet recruitingInflammatory Bowel Diseases | Crohn Disease | Crohn Colitis | Crohn's Ileocolitis | Crohn's Gastritis | Crohn's Jejunitis | Crohn's Duodenitis | Crohn's EsophagitisUnited States
-
Richard Burt, MDTerminatedCROHN'S DISEASEUnited States
-
Agomab Spain S.L.RecruitingFibrostenotic Crohn's DiseaseUnited States, Italy, Poland, Spain, Denmark, Austria, Canada, Germany
-
AbbVieActive, not recruitingCrohn's Disease (CD)United States, Belgium, Canada, Czechia, Denmark, France, Germany, Hungary, Israel, Italy, Netherlands, New Zealand, Norway, Poland, Romania, Slovakia, Spain, United Kingdom
-
AbbVieActive, not recruitingCrohn's Disease (CD)United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Czechia, France, Germany, Greece, Hungary, Israel, Italy, Korea, Republic of, Mexico, Netherlands, Poland, Romania, Russian Federation, Slo... and more
-
University Hospital, LilleMinistry of Health, FranceTerminatedCrohn's Disease AggravatedFrance
-
TakedaRecruitingCrohn's Disease (CD)United States, Australia, Israel, Belgium, Hungary, Canada, China, Croatia, Czechia, Greece, Italy, Japan, Korea, Republic of, Poland, United Kingdom, Lithuania, Slovakia, Spain
-
Weill Medical College of Cornell UniversityThe Kenneth Rainin FoundationRecruitingCrohn's Disease (CD)United States
Clinical Trials on THC 5mg/ml and CBS 50mg/ml
-
Reza Dana, MDCompletedCorneal NeovascularizationUnited States
-
Jiangsu Kanion Pharmaceutical Co., LtdBeijing Bionovo Medicine Development Co., Ltd.Completed
-
Spanish Cooperative Group for the Treatment of...Merck Sharp & Dohme LLCTerminated
-
Merz Pharmaceuticals GmbHCompletedHealthy Volunteers and Glaucoma PatientsGermany
-
Murdoch Childrens Research InstituteCompletedTourette Syndrome in AdolescenceAustralia
-
Asan Medical CenterNot yet recruitingGynecologic CancerKorea, Republic of
-
Ain Shams UniversityCompletedPain After Knee ArthroscopEgypt
-
University of PatrasUnknownStillborn Caesarean SectionGreece
-
Georg-Christian FunkUnknownPulmonary Disease, Chronic ObstructiveAustria
-
Zurita Laboratorio Farmaceutico Ltda.Unknown